Reflections on Psychiatry & Psychology

Introduction Ketamine, an NMDA receptor antagonist, has shown promise in the treatment of various psychiatric disorders, including depression and PTSD. Its rapid-acting therapeutic effects have made it an appealing option in clinical settings under strict supervision. However, the trend towards take-home ketamine, facilitated through prescriptions for nasal sprays and oral lozenges, raises significant safety and efficacy concerns. This blog entry explores some of the reasons

Zuranolone (Zurzuvae) is the first oral GABA-modulating antidepressant for postpartum depression. Taken for 14 days, it can improve symptoms within 3 days; benefits may last weeks. Common side effects include drowsiness and dizziness.

There are several exciting developments in the field of antidepressants, with various drugs currently in the pipeline. still in various stages of development. Clinical trials are ongoing to evaluate their safety, effectiveness, and potential side effects.

Dextromethorphan (DXM), found in cough meds, acts like mild ketamine. Combined with bupropion to slow its breakdown, it works quickly for depression. This combo was FDA-approved in 2022 as Auvelity.

Drug labels can mislead: meds are named for first uses, but act by mechanism. Topiramate (Topamax) began as seizure and migraine treatment, yet is also used off-label for mood stabilization or weight loss, among others.